Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials
| dc.rights.license | open | en_US |
| dc.contributor.author | MADELAIN, V. | |
| dc.contributor.author | MENTRE, F. | |
| dc.contributor.author | BAIZE, S. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | ANGLARET, Xavier | |
| dc.contributor.author | LAOUENAN, C. | |
| dc.contributor.author | OESTEREICH, L. | |
| dc.contributor.author | NGUYEN, T. H. T. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MALVY, Denis
ORCID: 0000-0003-1948-9355 IDREF: 148480993 | |
| dc.contributor.author | PIORKOWSKI, G. | |
| dc.contributor.author | GRAW, F. | |
| dc.contributor.author | GUNTHER, S. | |
| dc.contributor.author | RAOUL, H. | |
| dc.contributor.author | DE LAMBALLERIE, X. | |
| dc.contributor.author | GUEDJ, J. | |
| dc.date.accessioned | 2021-02-04T14:30:40Z | |
| dc.date.available | 2021-02-04T14:30:40Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 2163-8306 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26134 | |
| dc.description.abstractEn | In 2014, our research network was involved in the evaluation of favipiravir, an anti‐influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions among the virus, the innate and adaptive immune response, and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/us/ | * |
| dc.subject | IDLIC | |
| dc.title.en | Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials | |
| dc.title.alternative | CPT: pharmacometrics & systems pharmacology | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/psp4.12510 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 32198838 | en_US |
| bordeaux.journal | CPT: Pharmacometrics and Systems Pharmacology | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | IDLIC | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03131673 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-02-04T14:30:45Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=CPT:%20Pharmacometrics%20and%20Systems%20Pharmacology&rft.date=2020&rft.eissn=2163-8306&rft.issn=2163-8306&rft.au=MADELAIN,%20V.&MENTRE,%20F.&BAIZE,%20S.&ANGLARET,%20Xavier&LAOUENAN,%20C.&rft.genre=article |
